THE ROLE OF ANTI-AGGREGATE THERAPY IN THE COMPLEX TREATMENT OF TRANSITOR-ISCHEMIC ATTACKS AND IN THE PREVENTION OF ISCHEMIC STROKE IN MIA EMPLOYEES
Keywords:
transient ischemic attack, cardiomagnil, ischemic stroke, preventionAbstract
72 patients were examined, group 1 - with transient ischemic attacks (TIA) (42 patients) and the second group – patients who had an ischemic stroke (AI) and had a history of TIA (30 patients). Transcranial Dopplerography, ultrasound dopplerography of brachiocephalic vessels with duplex scanning, and blood coagulation parameters were performed. Clopidogrel was prescribed at a dosage of 75 mg 1 time per day. The most common causes of TIA development were occlusive BCA lesions in combination with violations of the rheological properties of blood. On the background of antiplatelet therapy with Clopidogrel, there was a positive dynamics of rheological properties of blood, more pronounced in patients with TIA, compared with patients who underwent AI on the background of TIA.
References
Гафуров Б.Г., Ш.Х.Арифджанов и др. «Инсульт в молодом возрасте» Ж-л «Неврология» №1, Ташкент – 2006
1. Скворцова В.И., Чазова И.Е., Стаховская Л.В. Вторичная профилактика инсульта. М.: ПАГРИ, 2002; 118 с. 2. Инсульт: принципы диагностики, лечения и профилактики. /Под ред. Н.В. Верещагина, М.А. Пирадова, З.А. Суслиной. - М.: Интермедика, 2002. - 208с. 3.Суслина З.А., Танашян М.М. Антиагрегантная терапия при ишемических цереброваскулярных заболеваниях. Пособие для практикующих врачей. М., 2003; 40 с. 4.Ушкалова Е.А. Добавление клопидогрела к ацетилсалициловой кислоте может быть полезно больным с симптоматическим атеротромбозом, но не рекомендуется для пациентов с множественными факторами риска: результаты исследования CHARISMA/Фарматека, 2006; 13: 16–8. 5. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002; 324: 71–86.
Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996; 60: 197–9.
Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66: 255.
Awtry E.H. Loscalzo J. Aspirin. Circulation. 2000;101: 1206–18.
Latini R., Cerletti C., de Gaetano G., and oth. Comparative bioavailability of aspirin from buffered, enteric–coated and plain preparations. Int J Clin Pharmacol Ther Toxicol. 1986; 24: 313–318.
CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRI. Lancet 1996; 348: 1329–39.
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly. Department of Neurology, University of Kuopio, Finland. Acta Neurol Scand 1993; 87 (2):
European Stroke Initiative- Recommendations for stroke management, 2003.
Ischemic Cerebrovascular Disease./ H. Adams, V. Hachinski, J. Norris/ - Oxford University press, 2001. - 575 p.
Stroke prevention by the practitioner./ Ed. J. Bogousslavsky. - Cerebrovascular Diseases, 1999. - 9.-S4.- 70p.
The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–73.
Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy. J Clin Gastroenterol. 1990;12: 10–13.
Hawthorne A.B., Mahida Y.R., Cole A.T., Hawkey C.J. Aspirin–induced gastric mucosal damage: prevention by enteric–coating and relation to prostaglandin synthesis. Br J Clin Pharmacol. 1991; 32: 77–83.
Cox D.B.Sc., Maree A., Dooley M., and oth. Coated aspirin less effective for anti–clotting than uncoated aspirin. The American Heart Association’s 5th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. Meeting Report. 05.06.2004.
Roderick P.J., Wilkes H.C., Meade T.W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 1993; 35: 219–226.
Kelly J.P., Kaufman D.W., Jurgelon J.M., and oth. Risk of aspirin–associated major upper–gastrointestinal bleeding with enteric–coated or buffered product. Lancet. 1996; 348: 1413–1416.
